ArQule Inc. entered a partnership on the lead program from its Cancer Survival Protein modulation program, a deal worth up to $123 million with Kyowa Hakko Kogyo Co. Ltd. (BioWorld Today)

ArQule Inc. entered a partnership on the lead program from its Cancer Survival Protein modulation program, a deal worth up to $123 million with Kyowa Hakko Kogyo Co. Ltd. (BioWorld Today)